Skip to main content

Table 1 Summary of pediatric rheumatology patient demographics, neoplasms and medications

From: Development of neoplasms in pediatric patients with rheumatic disease exposed to anti-tumor necrosis factor therapies: a single Centre retrospective study

Patient ID/ gender

Age at diagnosis of rheumatologic disease (years)

Age at diagnosis of neoplasm (years)

Neoplasm

Anti-TNFα (dose/Duration)

Time from

Rheumatologic diagnosis to neoplasm (years)

Time from start of anti-TNFα to neoplasm (years)

Concomitant and previous DMARD, cytotoxic agent and other Biologic (years)

Other concomitant and previous medications

Family history of malignancy

A/Female

Extended oligo JIA (1.6 years)

17

Ewing’s sarcoma

etanercept 25 mg biweekly × 2.6 years

16.7

5.3

methotrexate (7.2),

leflunomide (0.2)

naprosyn, prednisone, folic acid

Unknown

B/Female

Poly JIA (8.2 years)

24

renal clear cell carcinoma

etanercept 25 mg weekly ×  4.8 years,

infliximab 400 mg x one dose

15.8

10.6

from etanercept,

4.4 from infliximab

rituximaba (2 doses),

methotrexate (6.2),

leflunomide (0.2), sulfasalazine (0.9), azathioprine (1.2), cyclosporine A (1.5)

naprosyn, prednisone, hydroxychloroquine, amitriptyline, oxycodone, depo-provera, folic acid

Unknown

C/Female

Extended oligo JIA with anterior uveitis (2.0 years)

14

benign pilo-matricoma

infliximab 200–500 mg monthly ×  0.25 years

12.7

1.3

cyclosporine A (3.2), azathioprine (4.3),

methotrexate (6.0), leflunomide (2.8)

hydroxychloroquine,

acetazolamide,

alendronate,

iron, calcium

Multiple family members with colon cancer

D/Male

Idiopathic uveitis

(10.8 years)

16

naso-pharyngeal cancer

infliximab 300–400 mg monthly ×  3.3 years

5.3

3.3

methotrexate (4.7)

folic acid

Maternal grandfather with lung cancer; Maternal grandmother with cervical cancer

E/Female

Systemic JIA (4.7years)

16

hepatic T-cell lymphoma

etanercept 10 mg biweekly × 0.1 years,

infliximab (10 mg/kg) monthly ×  1.7 years

11.8

9.9 from etanercept,

8.6 from infliximab

anakinraa (1.9),

cyclosporine A (0.9),

methotrexate (3.6),

tacrolimus (5.0), thalidomide (0.6),

etoposide (6 doses)

prednisone

Unknown

F/Male

Polyarteritis Nodosa (1.1 years)

14/19

lympho-proliferative disease (age 14);

renal clear cell carcinoma (age 19)

infliximab (100 mg) monthly ×  4.8 years

14.1 to lympho-proliferative disease;

18.6 to renal clear cell carcinoma

4.8 to lympho-proliferative disease;

9.3 to renal clear cell carcinoma

methotrexate (1.2), azathioprine (unknown),

cyclophosphamide (1.5)

prednisone, enalopril, amlodipine,

sulfamethoxazole, ranitidine, testosterone, protropin, nutropin, insulin, metformin, ferrous fumarate

Mother with breast cancer (deceased at age 31); Half-brother with suspected autoimmune lympho-proliferative disorder

Median (IQR)

3.4 (1.7–7.3)

16.3 (15.3–17.9)

5.0 (3.6–7.7)

methotrexate: 5.4 (3.9–6.1)

  1. JIA = juvenile idiopathic arthritis
  2. aOther Biologic (non-anti-TNF)